Don’t let your #EGFR #Exon20 and #HER2 #Exon20 patients miss out on the wonderful, caring community of patients and care partners (+ family members) in the multi-stakeholder @Exon20Group We have peer-to-peer counseling through our Angel Buddies program, oncology nursing services, weekly virtual meetings, and direct patient navigation plus 20 closed Facebook groups and Inspire. Ami and mobo as well as the drugs in the clinical trials pipeline are vitally important & manageable. We are looking for additional investigators, so let us know! Clinicians, molecular profiling labs welcome. Join our Exon 20 International Research Consortium! All services are free, exon20group.org & marcia@exon20group.org

Good news for C797S patients and families for a much-needed TKI.

Update from SOLARA trial of BH-30643, a macrocyclic, mutant-selective, CNS penetrant EGFR TKI at #WCLC26. In EGFR C797S, RR 45% (18/40) with DCR 88% and 63% of pts still on therapy. Low discontinuation from TRAE (3%) with only 1% pneumonitis. Has fast-track designation from FDA.

Join us in Washington, DC on Saturday, October 10 for #DCLung26 - a one-day, comprehensive, multidisciplinary, discussion-based lung cancer CME update! Dr. @NaglaAKarimMD joins as faculty to discuss the latest advances in treating EGFR mutant NSCLC! medstarhealth.org/dclung

In Beamion LUNG-1 with zongertinib, 8 paired tissue results from pts with PD showed two acquired HER2 mutations: T862A and S783C. Notably absent were T798I (gatekeeper) and C805S (binding site). The acquired mutations not detected in plasma. #WCLC26 @dplanchard

Early insights into resistance to HER2 TKIs in NSCLC emerged at #WCLC26. Zongertinib & sevabertinib now both approved as 1L+ treatment for advanced NSCLC with a HER2 TKD mt. While efficacy similar, these are distinct agents and we need to learn how to leverage those differences.

Important study by fellow CANCAN advocate Barry D. Stein and colleagues on importance of patient-centered nutrition care in the management of #colorectalcancer. #cancercachexiaawarenessday @CancerGrand @coloncanada mdpi.com/4075526 #mdpicurroncol via @CurrentOncology

ASBM’s former chairman, Dr. Madelaine Feldman, participated in the first panel of yesterday's #AfPASummit26: “The bottom line in pricing needs to be brought back to the patient’s ability to access the medication. For example -Many times affordability could be achieved by allowing the patient to pay their cost share (co-insurance) on the lowest post rebate/discount price of the drug.—including by basing cost-sharing on the lowest post-rebate price, especially for Part B drugs." @MattieRheumMD @patientaccess @LADAOrg @GlobalCRC @WarOnCancer @CSROAdvocacy

Updates in 9/2026 NCCN NSCLC Guidelines: sevabertinib as 1L option for HER2 mt NSCLC & daraxonrasib (off label at 200mg daily dosing) added to consider in pts with KRAS mutant NSCLC. In phase I/II, post chemo-IO, RR ~ 42%, DOR ~1y. Worth pursuing if no access to clinical trials.

I remember Dr. @geoff_oxnard et al first uncovering this founder effect for EGFR T790M while I was still at @GO2forLungCancr. I am glad to see the work validated in a much larger cohort of individuals. Being from SC and with Scotch-Irish ancestry, it's of interest to me!

The significance of the new study published in Science for a founder effect of EGFR T790M in #lungcancer is that it built upon and validated a previous finding in a much larger cohort ascopubs.org/doi/10.1200/JCO…

WCLC 2026 update! New developments in HER2-mutant #NSCLC 🫁 Thoracic oncologist Dr @JSabari shares expert insights on data from: - DESTINY-Lung04 - SOHO-01 - Beamion LUNG-1 📹 Get Dr Sabari’s key clinical takeaways in this video Watch his full video update and get a more detailed look at the data in the slides: cor2ed.com/lung-connect/prog… 🤝 Endorsed by @WarOnCancer, @Exon20Group & @BiomarkerCo Supported by an Independent Educational Grant from Bayer. For HCPs only. #MedEd #thoraciconcology #WCLC2026 #lcsm #oncology #OncTwitter #WCLC26

🔥EGFR PACC mutations & exon 20 insertions in NSCLC: a rapidly evolving therapeutic landscape 🆙 @JCO_ASCO 🎯PACC (G719X, S768I, E709X, L747X): 2nd-gen TKIs preferred 🎯Common+PACC compound mutations: 3rd-gen TKIs 🎯Ex20ins: amivantamab, sunvozertinib (WU-KONG28), zipalertinib & firmonertinib show meaningful activity 🎙Dr. Federico Monaca @caliraf @LeXiuning #LCSM @ASCO @OncoAlert @Larvol @EGFRResisters @Exon20Group ascopubs.org/doi/full/10.120…

Update from WCLC 2026: The latest in HER2-mutant NSCLC >> From thoracic oncologist Dr @JSabari What do DESTINY-Lung04, and new data from SOHO-01 & Beamion LUNG-1 mean for HER2-mutant NSCLC? 📺Watch to find out Endorsed by @WarOnCancer, @Exon20Group & @BiomarkerCo Supported by an Independent Educational Grant from Bayer. For HCPs only.

TROP2-ADCs are emerging as a promising therapeutic option across multiple treatment settings in #NSCLC🫁 What do HCPs need to know about the efficacy and safety profiles and potential AEs of these treatments? How can we optimise the treatment experience and improve outcomes for patients? Get answers to these questions, and learn more about TROP2-directed ADCs for non-small cell #lungcancer ⤵️ 📹Full on-demand video + slides: cor2ed.com/lung-connect/prog… w/ Prof. Nicolas Girard (@nicogirardcurie), Dr Louise Lim, Dr Jacob Sands (@sands_jacob) & Nurse Practitioner Mrs Stephanie McDonald 🤝Endorsed by @WarOnCancer, @Exon20Group & @BiomarkerCo Supported by an Independent Educational Grant from AstraZeneca #MedEd #Oncology #LCSM #MedTwitter

🌟 The Human. Connection. The Lives Changed. 🤝 With our patients, we can go further @JFreemanDaily @ros1cancer @ros1cancer @ROS1CancerSpain @LUNGevity @GO2forLungCancr @LungCancerEu @ALKPositiveinc @ALKpositiveINT @EGFRResisters @Exon20Group @kRasKickers @metcrusaders @BrafBombers @RETpositive @RETRenegades @NTRKers #LCSM @IASLC @OncoAlert

#WCLC26 Presidential Symposium Day 2 🔥#DESTINY-Lung04: First-line trastuzumab deruxtecan (TDxd) vs chemo IO in #HER2-mutant metastatic NSCLC. 🎙️@JuliaRotow ▶️ Median PFS: 14.3 vs 8.3 mo ▶️ HR 0.63; P<0.0001 ▶️ ORR: 70.0% vs 44.5% ▶️ DOR: 13.7 vs 9.7 mo ⬆️ crossover ⚠️Grade ≥3 TRAEs similar 🫁Adjudicated drug-related ILD: 20.8% 👉🏽👉🏽TDxd is more active than chemoIO, competes w oral drugs in market w less chemo side effects 👉🏽👉🏽some caution about ILD but overall we have used this drug safely in 2nd line. @Exon20Group #lcsm @IASLC

DESTINY-Lung04 at #WCLC26 In 1L HER2-mutant advanced NSCLC, T-DXd significantly improved PFS vs pembrolizumab + chemotherapy: mPFS 14.3 vs 8.3 months (HR 0.63; P<0.0001) ORR: 70.0% vs 44.5% However, no OS benefit was observed at this analysis (29.3 vs 33.1 months; HR 1.15). The first Phase 3 trial showing benefit of a HER2-directed therapy vs SOC in this setting. @OncoAlert @GlopesMd @ManuelDomine @StephenVLiu @weoncologists @OpenMedKate

Well said!

#WCLC26 Presidential Symposium Day 2 🔥#PAPILLON: First-Line Amivantamab-Chemotherapy vs Chemotherapy in NSCLC With EGFR Exon 20 Insertions: Overall Survival update 🎙️ @chulkimMD 🎯 mOS: 34.3 mos amivantamab+chemo vs 27.9 mos with chemo ( HR 0.87)- crossover adjusted HR 0.57 ⚡️76% crossover 👉🏽current 1st line option in the US- soon to compete w new oral agents. @Exon20Group @EGFRResisters #lcsm

🆙#WCLC26 #LCSM Plenary Session 🔥PAPILLON: First-Line Amivantamab-Chemotherapy vs Chemotherapy in NSCLC With EGFR Exon 20 Insertions: Overall Survival 🎙️ @chulkimMD 🎯 OS HR 0.87 (95%CI 0.66-1.14) 🔢PL03.03 ☑️NCT04538664 🔗 cattendee.abstractsonline.co… @OncoAlert @Larvol @IASLC @EGFRResisters @Exon20Group